Pfizer inks deal with nanotechnology drugmaker


QDOTS imagesCAKXSY1K 8CAMBRIDGE, Mass. (AP)BIND Therapeutics said Wednesday that Pfizer Inc. has agreed to pay at least $160 million per drug as part of a collaboration to develop targeted medicines using nanotechnology which use particles measured in billionths of a meter.

BIND is developing an experimental group of targeted, programmable medicines called Accurins to treat cancer, heart disease and inflammatory disorders. The privately held company’s technology comes from two laboratories that specialize in nanotechnology at Harvard Medical School and the Massachusetts Institute of Technology.

Pfizer will make initial payments of roughly $50 million, plus $160 million in regulatory and milestone payments for each targeted drug, according to an announcement from BIND.

Both companies will work on early-stage research for the drugs, and Pfizer will have the exclusive option to develop and market any products produced from the collaboration.

BIND has one product in early-stage clinical testing called Bind-014, a targeted Accurin that contains the chemotherapy drug docetaxel. The product is designed to attach itself to a protein that is expressed in some cancer cells and new blood vessels that feed tumors.

In an unrelated announcement Wednesday, the Children’s Hospital of Philadelphia said it will collaborate with Pfizer on therapies for children. Pfizer has research relationships with 21 academic hospitals throughout the U.S. with the aim of developing new products.end of story marker

Nanotechnology: Drug Delivery Market 2012-2016


IOTA NanoSolutions Ltd., Lena Nanoceutics Ltd., GlaxoSmithKline plc, Celgene Corp., and SkyePharma Dominate the Market

DUBLIN —

QDOTS imagesCAKXSY1K 8Research and Markets (http://www.researchandmarkets.com/research/rcp9ds/global) has announced the addition of the “Global Nanotechnology Drug Delivery Market 2012-2016” report to their offering.

 

TechNavio’s analysts forecast the Global Nanotechnology Drug Delivery market to grow at a CAGR of 73.97 percent over the period 2012-2016. One of the key factors contributing to this market growth is the low R&D cost. The Global Nanotechnology Drug Delivery market has also been witnessing an increase in customer support services. However, the increasing safety concerns could pose a challenge to the growth of this market.

Commenting on the report, an analyst from TechNavio’s Healthcare team said: ”Pharmaceutical and biotechnology companies are focusing on capitalizing on the potential of nanotechnology-enabled drug delivery. Nanotechnology-enabled drug delivery systems are helping pharmaceutical and biotechnology companies to counter the threat of generics.

Reformulation helps in extending the product life cycle, and novel reformulations help an existing drug candidate to qualify as a new chemical entity. This increases profitability and discourages competition during the drug’s most profitable years.”
According to the report, increasing government funding is one of the major drivers in the Global Nanotechnology Drug Delivery market. Government programs in various countries such as the US, the UK, Germany, and China exist for funding various R&D initiatives in nanotechnology, which is boosting the growth of the market.

Further, the report states that various manufacturing issues constitute one of the major challenges in the Global Nanotechnology Drug Delivery Market.

The key vendors dominating this space are IOTA NanoSolutions Ltd., Lena Nanoceutics Ltd., GlaxoSmithKline plc, Celgene Corp., and SkyePharma plc.

The other vendors mentioned in the report are Merck & Co. Inc., Pfizer Inc., AlphaRx Inc., Amgen Inc., Angiotech Pharmaceuticals Inc., Biophan Technologies Inc., Calando Pharmaceuticals Inc., Cephalon Inc., Cerulean Pharma Inc., Copernicus Therapeutics Inc., CritiTech Inc., CytImmune Sciences Inc., Elan Corp. plc, Debiotech SA, F. Hoffmann-La Roche Ltd., Nano Interface Technology Inc., Spherics Inc., Spectrum Pharmaceuticals Inc., SoluBest Ltd., Sigma-Tau Pharmaceuticals Inc., PharmaNova Inc., Particle Sciences Inc., Novavax Inc., Nanotherapeutics Inc., NanoSight Ltd., NanoCarrier Co. Ltd., NanoBioMagnetics Inc., Nano Interface Technology Inc., Merck Sharp & Dohme Corp., Kuecept Ltd., and Izon Science Ltd.

Key questions answered in this report:

– What will the market size be in 2016 and what will the growth rate be?

– What are the key market trends?

– What is driving this market?

– What are the challenges to market growth?

– Who are the key vendors in this market space?

– What are the market opportunities and threats faced by the key vendors?

– What are the strengths and weaknesses of each of these key vendors?

You can request one free hour of analyst time when you purchase this report. Details provided within the report.

For more information visit http://www.researchandmarkets.com/research/rcp9ds/global